Efficacy News and Research

RSS
KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Nanotechnology might provide greater efficacy of medicines for brain disease

Nanotechnology might provide greater efficacy of medicines for brain disease

Combination therapy may overcome Herceptin-resistant breast cancer

Combination therapy may overcome Herceptin-resistant breast cancer

Alzheimer's vaccine - First evidence for efficacy

Alzheimer's vaccine - First evidence for efficacy

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints

Supernus SPN-812 Phase IIa U.S. clinical trial in ADHD meets primary endpoints

FDA approves Lantheus Medical Imaging's SPA for flurpiridaz F-18 Phase 3 trial in coronary artery disease

FDA approves Lantheus Medical Imaging's SPA for flurpiridaz F-18 Phase 3 trial in coronary artery disease

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

Updated NCCN Guidelines for Breast Cancer outline expanded treatment options

Updated NCCN Guidelines for Breast Cancer outline expanded treatment options

Arena fourth quarter net loss decreases to $28.2 million

Arena fourth quarter net loss decreases to $28.2 million

Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex fourth quarter net loss increases to $7.0 million

Majority of men on ADT after prostatectomy gain weight during first year of therapy

Majority of men on ADT after prostatectomy gain weight during first year of therapy

Simcere files IND with SFDA of China for APX003 to treat cancer

Simcere files IND with SFDA of China for APX003 to treat cancer

Discovery: VPS4A enzyme plays a key role in release of HIV particles

Discovery: VPS4A enzyme plays a key role in release of HIV particles

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

FDA approves Matrix NDA for Zidovudine Tablets

FDA approves Matrix NDA for Zidovudine Tablets

Novartis new MS treatment receives Notice of Compliance in Canada

Novartis new MS treatment receives Notice of Compliance in Canada

Preliminary phase I trial results show safety of bone marrow stem cells in children with TBI

Preliminary phase I trial results show safety of bone marrow stem cells in children with TBI

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.